Comparative Pharmacology
Head-to-head clinical analysis: AVZIVI versus BEOVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVZIVI versus BEOVU.
AVZIVI vs BEOVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avizivi (avelumab) is a human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors. This restores anti-tumor immune responses, including T-cell activation and proliferation, by reversing PD-L1-mediated inhibition.
Brolucizumab is a humanized monoclonal antibody Fab fragment that inhibits vascular endothelial growth factor (VEGF)-A, preventing its binding to VEGFR-1 and VEGFR-2 receptors, thereby reducing endothelial cell proliferation, neovascularization, and vascular permeability.
IV 200 mg over 30 minutes on Day 1 of a 21-day cycle, in combination with paclitaxel and carboplatin; continue until disease progression or unacceptable toxicity.
0.5 mg (0.05 mL of 10 mg/mL solution) by intravitreal injection once every 4 weeks (monthly) for 12 months, then may be extended to once every 8 weeks (every 2 months) based on clinical response.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; prolonged to 24–48 h in moderate-to-severe renal impairment.
Terminal half-life approximately 26 days (range 23-31 days) in patients with neovascular age-related macular degeneration, supporting monthly intravitreal dosing.
Primarily renal excretion as unchanged drug (~70%) and glucuronide conjugate (~30%); biliary/fecal excretion accounts for <5%.
Primarily metabolic clearance; <1% excreted unchanged in urine. Biliary/fecal excretion not characterized for parent drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor